Journal of the American Chemical SocietyBiophysicsPeer-reviewed journal article
Design of Tau Aggregation Inhibitors Using Iterative Machine Learning and a Polymorph-Specific Brain-Seeded Fibril Amplification Assay
Alessia SantambrogioiD, Robert I. HorneiD, Michael A. MetrickiD, Nicholas C. T. Gallagher, Z. Faidon BrotzakisiD, Dillon J. RinauroiD, Ergina Vourkou, Katerina PapanikolopoulouiD, Efthimios M. C. SkoulakisiD, Sara Snogerup LinseiD, Byron W. CaugheyiD, Michele VendruscoloiD
Abstract
The aggregation of tau into amyloid fibrils is associated with Alzheimers disease (AD) and related tauopathies. Since different tauopathies are characterised by the formation of distinct tau fibril morphologies, it is important to combine the search of tau aggregation inhibitors with the development of in vitro tau aggregation assays that recapitulate aggregation as it may occur in the brain. Here we address this problem by reporting an in vitro tau aggregation assay in which AD brain homogenates are used to seed the generation of first-generation tau fibrils in a polymorph-specific manner under quiescent conditions. These fibrils are then used to create amyloid seed libraries from which second-generation kinetic assays can be readily performed. Using this strategy, we illustrate an iterative machine learning method for the identification of small molecules for the polymorph-specific inhibition of the in vitro formation of tau fibrils. We further show that the small molecules selected by this procedure are potent inhibitors in a Drosophila tauopathy model.
- organism: Drosophila
- assay: proteomics
- research focus: drug response / drug discovery
- approach: deep learning
- Citations
- 12
- FWCI
- 7.66
- Field percentile
- top 2%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Tryptanthrin Analogs Substoichiometrically Inhibit Seeded and Unseeded Tau4RD Aggregation
E. I. James, D. W. Baggett, … A. Nath·bioRxiv·Feb 2, 2024
- In vitro tau aggregation inducer molecules influence the effects of MAPT mutations on aggregation dynamics
D. J. Ingham, K. M. Hillyer, … T. C. Gamblin·bioRxiv·Aug 6, 2021
- Peptide-based inhibitors of Tau aggregation as a potential therapeutic for Alzheimer's disease and other Tauopathies
Anthony Aggidis, Shreyasi Chatterjee, … David Allsop·bioRxiv·Jun 4, 2021
- Baicalein suppresses Tau fibrillization by sequestering oligomers
S. Sonawane, A. Balmik, … S. Chinnathambi·bioRxiv·Jul 16, 2019
- Tau Disaggregation by a CNS-Permeable Small Molecule Reduces Fibril and Oligomer Burden and Preserves Proteostasis and Behavior
Nader Mostowfi, Ryan Patrick Foreman, … Paul M. Seidler·bioRxiv·Sep 1, 2026
- Tau amyloidogenesis begins with a loss of its conformational polymorphism
M. d. C. Fernandez-Ramirez, R. Hervas, … M. Carrion-Vazquez·bioRxiv·Jun 18, 2020